Compare LOAN & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOAN | VNRX |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 38.2M |
| IPO Year | 1999 | N/A |
| Metric | LOAN | VNRX |
|---|---|---|
| Price | $4.87 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.17 |
| AVG Volume (30 Days) | 41.3K | ★ 2.6M |
| Earning Date | 10-24-2025 | 11-13-2025 |
| Dividend Yield | ★ 9.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $7,138,128.00 | $1,472,007.00 |
| Revenue This Year | N/A | $55.33 |
| Revenue Next Year | $4.47 | $493.79 |
| P/E Ratio | $10.41 | ★ N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $4.29 | $0.27 |
| 52 Week High | $6.05 | $0.94 |
| Indicator | LOAN | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.85 | 36.84 |
| Support Level | $4.64 | $0.28 |
| Resistance Level | $4.83 | $0.34 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 96.67 | 36.58 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.